After preclinical toxicologic study in baboons, we are conducting a phase I trial of malonatoplatinum, starting with 3 mg/kg and now reaching 1 mg/kg. Toxicity, mainly hematologic, was mild and our study was mainly limited by poor solubility. Regressions, which have been rare in the advanced-tumor patients, have been observed in three patients considered as clinically resistant to cisdichlorodiammino-platinum (DDP). Malonatoplatinum pharmacokinetics appeared similar to those of DDP as far as total platinum is concerned.
CITATION STYLE
Ribaud, P., Kelsen, D. P., Alcock, N., Garcia-Giralt, E., Dubouch, P., Young, C. C., … Mathé, G. (1980). Preclinical and phase I studies of malonatoplatinum. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer, 74, 156–162. https://doi.org/10.1007/978-3-642-81488-4_20
Mendeley helps you to discover research relevant for your work.